case_images: PMC10959001_01
case_images: Pathological examination to confirm that the pulmonary metastasis (A) and uterine mass (B) were choriocarcinoma.
case_images: fonc-14-1345011-g001.jpg
case_images: PMC10959001_01_fonc-14-1345011-g001.jpg
case_images: f1
case_images: Pathological examination of the pulmonary metastasis confirmed choriocarcinoma ( Figure 1A ). The patient underwent hysterectomy and histological assessment confirmed that the uterine mass was choriocarcinoma ( Figure 1B ). The EMA-CO regimen was switched to etoposide, cisplatin, methotrexate, and dactinomycin (EP-EMA) chemotherapy after one course of postoperative chemotherapy, because of an unsatisfactory decrease in beta-hCG, and tislelizumab was added after one course of EP-EMA for the same reason.
case_images: Serum beta-hCG level returned to the normal range after eight cycles of chemotherapy.
case_images: fonc-14-1345011-g002.jpg
case_images: PMC10959001_01_fonc-14-1345011-g002.jpg
case_images: f2
case_images: After four cycles of EP-EMA chemotherapy combined with tislelizumab, her beta-hCG level returned to the normal range ( Figure 2 ), and pulmonary metastases were reduced ( Figures 3A-C ).
case_images: Multiple pulmonary metastases gradually subsided after six cycles (A), 12 cycles (B), and 3 months (C) of chemotherapy. The patient relapsed after eight maintenance treatments with tislelizumab (D).
case_images: fonc-14-1345011-g003.jpg
case_images: PMC10959001_01_fonc-14-1345011-g003.jpg
case_images: f3
case_images: After four cycles of EP-EMA chemotherapy combined with tislelizumab, her beta-hCG level returned to the normal range ( Figure 2 ), and pulmonary metastases were reduced ( Figures 3A-C ). No distant metastasis or recurrence were found until the eighth course of maintenance treatment with tislelizumab ( Figure 3D ).